Pulmonary Cell News Volume 5.37 | Sep 22 2016

TOP STORY

Inhibition of Acetyl-CoA Carboxylase Suppresses Fatty Acid Synthesis and Tumor Growth of Non-Small-Cell Lung Cancer in Preclinical Models

Investigators provide genetic and pharmacological evidence that in preclinical models acetyl-CoA carboxylase is required to maintain the de novo fatty acid synthesis needed for growth and viability of non-small-cell lung cancer cells. [Nat Med] Abstract | Press Release | Video

(Ranked by impact factor of the journal)

Palmitoyl Acyltransferase DHHC21 Mediates Endothelial Dysfunction in Systemic Inflammatory Response Syndrome

Scientists reported a novel function of DHHC-containing palmitoyl acyltransferases in mediating endothelial inflammation. [Nat Commun] Full Article

Loss of Lysyl Oxidase-Like 3 Attenuates Embryonic Lung Development in Mice

The authors investigated a possible role for lysyl oxidase-like 3 (LOXL3) in mouse embryonic lung development. LOXL3-deficient mice displayed reduced lung volumes and weights, diminished saccular spaces, and deformed and smaller thoracic cavities. [Sci Rep] Full Article

Adenovirus-Mediated Foxp3 Expression in Lung Epithelial Cells Reduces Airway Inflammation in Ovalbumin and Cockroach-Induced Asthma Model

The authors evaluated the functions of Foxp3 in ovalbumin- and cockroach-induced asthma models. [Exp Mol Med] Full Article

Δ⁹-Tetrahydrocannabinol Reverses TNFα-Induced Increase in Airway Epithelial Cell Permeability through CB₂ Receptors

Researchers investigated the effects of Δ⁹-tetrahydrocannabinol on bronchial epithelial cell permeability after exposure to the pro-inflammatory cytokine, TNFα. [Biochem Pharmacol] Abstract

Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling

Investigators present a method for the generation of self-assembled human lung tissue and its potential for disease modeling and drug discovery for lung diseases characterized by progressive and irreversible scarring such as idiopathic pulmonary fibrosis. [Stem Cells Transl Med] Full Article | Press Release

Structural Basis for KCNE3 Modulation of Potassium Recycling in Epithelia

Researchers used an integrative structural model to guide electrophysiological studies that illuminate the molecular basis for how estrogen exacerbates cystic fibrosis (CF) lung disease in female patients, a phenomenon known as the “CF gender gap.” [Sci Adv] Abstract | Press Release | Video

LUNG CANCER

Chronic Stress Faciliates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells

Investigators showed that chronic stress in mice chemically or genetically initiated for lung cancer leads to the release of norepinephrine and other catecholamines, thereby promoting lung tumorigenesis. [Cancer Res] Abstract

INO80 Is Required for Oncogenic Transcription and Tumor Growth in Non-Small Cell Lung Cancer

Researchers showed that the INO80 chromatin remodeling complex is required for oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC). Ino80, the SWI/SNF ATPase in the complex, is highly expressed in NSCLC cells compared with normal lung epithelia cells. [Oncogene] Abstract

The MicroRNA-182-PDK4 Axis Regulates Lung Tumorigenesis by Modulating Pyruvate Dehydrogenase and Lipogenesis

Scientists showed that microRNA-182 (miR-182) suppresses pyruvate dehydrogenase (PDH) kinase 4 (PDK4) and promotes lung tumorigenesis. miR-182 is dysregulated and inversely correlated with PDK4 in human lung adenocarcinomas. The miR-182-PDK4 axis regulates lung cancer cell growth by modulating the activity of PDH, the gatekeeping enzyme of pyruvate flux into acetyl-CoA, and subsequently de novo lipogenesis of cancer cells. [Oncogene] Abstract

4-Cholesten-3-One Suppresses Lung Adenocarcinoma Metastasis by Regulating Translocation of HMGB1, HIF1α and Caveolin-1

Researchers explored the possibility that 4-cholesten-3-one inhibited adenocarcinoma (ADC) metastasis. Low-dose 4-cholesten-3-one significantly restrained ADC cells migration and invasion with little effects on cells viabilities. [Cell Death Dis] Full Article

ALK Mutation and Inhibition in Lung Cancer

The authors summarize the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. announced that the company will present a poster describing the relative bioavailability of CTP-656 under fasted and fed conditions along with results from the Phase I multiple ascending dose study. [Press release from Concert Pharmaceuticals, Inc. discussing research presented at 30th Annual North American Cystic Fibrosis Conference, Orlando] Press Release

OSE Immunotherapeutics to Present Atalante 1, the Registration Clinical Trial of Tedopi^®, Ongoing in the U.S. And in Europe, at the World Conference on Lung Cancer

OSE Immunotherapeutics SA will present a poster describing the updated design of the registration clinical trial Atalante 1. This trial with Tedopi^® is ongoing internationally in non-small Cell lung cancer. [Press release from OSE Immunotherapeutics SA (Business Wire) discussing research presented at the World Conference on Lung Cancer, Vienna] Press Release

Agilent Technologies Launches New Panel for Fast FISH Testing

Agilent Technologies announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow. [Agilent Technologies Inc.] Press Release

Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase III Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients

Aradigm Corporation announced that the last patient has completed the final dosing visit in the ORBIT-3 and ORBIT-4 Phase III clinical studies of Pulmaquin^®, Aradigm’s proprietary inhaled ciprofloxacin, an investigational new medication being studied for the treatment of patients with non-cystic fibrosis bronchiectasis who have chronic lung infections with Pseudomonas aeruginosa. [Aradigm Corporation (Business Wire)] Press Release

FDA Clears Way for ClearRead CT Software

Riverain Technologies announced ClearRead CT, a breakthrough nodule detection application, has received clearance from the Food and Drug Administration (FDA). [Riverain Technologies] Press Release

Facebook Couple Commits $3 Billion to Cure Disease

Facebook co-founder Mark Zuckerberg and his wife, physician and educator Priscilla Chan, have enlisted a ‘dream team’ of scientific leaders to oversee a US $3-billion effort to boost basic research. [Nature News] Editorial

Titanic Clash over CRISPR Patents Turns Ugly

Much of the focus is on the teams centred at Berkeley and the Broad Institute, whose ‘foundational’ patents cover a wide swathe of CRISPR–Cas9 applications. Although Berkeley’s team filed for a patent first, the Broad opted for an expedited review process, and its patents were granted earlier. [Nature News] Editorial

Spain Joins Bandwagon for ‘Openness’ About Animal Research

The Spanish scientific community has pledged to become more transparent about animal research. Ninety research centers, universities, scientific societies, and companies around Spain have adopted a set of standards, launched by the Confederation of Spanish Scientific Societies, on how research organizations should open up communication channels about their use of laboratory animals. [Science Insider] Editorial

New Fellowship Aims to Increase Diversity in the Life Sciences

A new program aims to launch the careers of life scientists from underrepresented groups by providing up to 8 years of support, covering both the postdoctoral training and junior faculty stages. The Howard Hughes Medical Institute’s Hanna H. Gray Fellows Program will award up to 15 recipients with $60,000 of salary support and $20,000 in flexible funds paid to their institutions for each of up to 4 years of postdoc training. [Science Insider] Editorial

NEW Challenges, Solutions and Progress in Stem Cell Medicine
February 18-21, 2017
Carlsbad, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Research Fellowship – Lung Disease (Johns Hopkins University)

Postdoctoral Fellow – Regenerative Medicine/Biomedical Science (University of California)

Scientist/Senior Scientist – Nanoparticle Research and Drug Delivery (Moderna Therapeutics)

Chair in Medical Biology – Head of the Department of Biology (Masaryk University)

Postdoctoral Fellow – Directed Differentiation of Human Pluripotent Stem Cells into Lung and Airway Epithelial Cells (Columbia University Medical Center)

Tenure-Track Faculty Positions – Inflammation and Inflammatory Lung Diseases (Temple University)

Postdoctoral Research Fellowship – Translational Fibrosis Research (RWTH Aachen University)

Postdoctoral Fellow – Cell and Animal Models of Lung Cancer (University of Kentucky Markey Cancer Center)

Robert Stowell Chair – Experimental Pathology (University of California, Davis)

Postdoctoral Research Fellow – Complex Lung Diseases (National Jewish Health)

Non-Clinical Lecturer – Reader in Respiratory Science (Imperial College London)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.